Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17201780 | 0.86 | ALDH1A1 (0.55) | HTR6 | |
| SCHEMBL3609792 | 0.83 | HTR6 (0.66) | HTR6HTR1AHTR2AHTR7HTR5A | |
| SCHEMBL30735820 | 0.83 | HTR6 (0.66) | HTR6HTR1AHTR2AHTR7HTR5A | |
| Hydrochloric Acid SCHEMBL6047117 | 0.82 | HTR6 (0.64) | HTR6HTR1AHTR2AHTR7HTR5A | |
| SCHEMBL18553769 | 0.81 | HTR6 (0.54) | HTR6HTR1AHTR2ADRD3HTR1D | |
| SCHEMBL1380651 | 0.79 | HTR6 (0.60) | HTR6HTR1AHTR2AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL5550931 | 0.79 | HTR6 (0.59) | HTR6HTR1AHTR2AHTR1DHTR1B | |
| SCHEMBL3796417 | 0.77 | HTR6 (1.00) | HTR6HTR1AHTR2AHTR7 | |
| SCHEMBL18553746 | 0.77 | HTR6 (0.89) | HTR6ADRB1HTR2CHTR2B | |
| SCHEMBL8632814 | 0.76 | HTR6 (0.67) | HTR6HTR1AHTR2AHTR7HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-6599904-B2 | 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-29 | — | — | US | disclosed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | HTR6 313/4885HTR1A 214/4885HTR2A 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.